Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Aug;8(16):1034.
doi: 10.21037/atm.2020.04.31.

More is not always better-what can be learned from the D-CARE trial

Georg Pfeiler  1 , Michael Gnant  2
Affiliations
Editorial

More is not always better-what can be learned from the D-CARE trial

Georg Pfeiler et al. Ann Transl Med. 2020 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.04.31). GP has received honoraria from Novartis, Roche, Amgen, Eli-Lilly, Pfizer, Astra Zeneca; MG has received institutional research support from AstraZeneca, Roche, Novartis, and Pfizer, and has received lecture fees, honoraria for participation on advisory boards, and travel support from Amgen, AstraZeneca, Celgene, Eli-Lilly, Invectys, Pfizer, Nanostring, Novartis, Roche, and Medison. MG has served as a consultant for AstraZeneca and Eli-Lilly, and an immediate family member is employed by Sandoz.

Comment on

References

    1. Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018;379:122-37. 10.1056/NEJMoa1803164 - DOI - PMC - PubMed
    1. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008;9:840-9. 10.1016/S1470-2045(08)70204-3 - DOI - PubMed
    1. Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 2006;24:5305-12. 10.1200/JCO.2006.07.5382 - DOI - PubMed
    1. Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015;386:433-43. 10.1016/S0140-6736(15)60995-3 - DOI - PubMed
    1. Olechnowicz SW, Edwards CM. Contributions of the host microenvironment to cancer-induced bone disease. Cancer Res 2014;74:1625-31. 10.1158/0008-5472.CAN-13-2645 - DOI - PMC - PubMed